In the last week, the Biotech industry is up 8.3%, with Sichuan Kelun-Biotech Biopharmaceutical up 28%. During this same period, the ImmuneOnco Biopharmaceuticals (Shanghai) underperformed, falling 16%. However, the industry is down 41% over the past year. Earnings are forecast to grow by 30% annually.
Has the Hong Kong Biotech Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Mon, 18 Mar 2024 | HK$366.5b | HK$47.5b | -HK$20,433,312,530.06 | 17.6x | -17.9x | 7.7x |
Wed, 14 Feb 2024 | HK$321.2b | HK$46.8b | -HK$20,174,942,054.91 | 15.6x | -15.9x | 6.9x |
Fri, 12 Jan 2024 | HK$385.8b | HK$46.9b | -HK$20,262,766,347.00 | 17.7x | -19x | 8.2x |
Sun, 10 Dec 2023 | HK$399.7b | HK$46.9b | -HK$20,222,468,345.00 | 17.7x | -19.8x | 8.5x |
Tue, 07 Nov 2023 | HK$430.1b | HK$45.3b | -HK$19,010,469,517.00 | 13.6x | -22.6x | 9.5x |
Thu, 05 Oct 2023 | HK$400.6b | HK$45.0b | -HK$19,133,521,889.00 | 13.7x | -20.9x | 8.9x |
Sat, 02 Sep 2023 | HK$410.0b | HK$45.2b | -HK$16,778,616,585.00 | 15x | -24.4x | 9.1x |
Mon, 31 Jul 2023 | HK$427.9b | HK$35.5b | -HK$23,380,251,031.00 | 28x | -18.3x | 12x |
Wed, 28 Jun 2023 | HK$393.2b | HK$35.4b | -HK$23,290,725,942.00 | 24.5x | -16.9x | 11.1x |
Fri, 26 May 2023 | HK$426.2b | HK$36.1b | -HK$23,813,255,373.00 | 29.5x | -17.9x | 11.8x |
Sun, 23 Apr 2023 | HK$441.1b | HK$36.9b | -HK$24,127,461,338.00 | 18.5x | -18.3x | 11.9x |
Tue, 21 Mar 2023 | HK$388.5b | HK$32.4b | -HK$35,354,889,097.00 | 22.5x | -11x | 12x |
Thu, 16 Feb 2023 | HK$426.4b | HK$34.7b | -HK$35,071,947,871.00 | 32.5x | -12.2x | 12.3x |
Sat, 14 Jan 2023 | HK$465.6b | HK$35.1b | -HK$35,473,049,138.00 | 32.1x | -13.1x | 13.3x |
Mon, 12 Dec 2022 | HK$393.0b | HK$33.6b | -HK$33,953,988,397.00 | 24.6x | -11.6x | 11.7x |
Wed, 09 Nov 2022 | HK$364.0b | HK$33.8b | -HK$32,491,041,863.00 | 18.5x | -11.2x | 10.8x |
Fri, 07 Oct 2022 | HK$297.9b | HK$34.0b | -HK$32,534,263,068.00 | 17.2x | -9.2x | 8.8x |
Sun, 04 Sep 2022 | HK$334.7b | HK$34.6b | -HK$33,887,082,201.00 | 15.6x | -9.9x | 9.7x |
Tue, 02 Aug 2022 | HK$324.6b | HK$32.9b | -HK$46,359,653,984.00 | 12.7x | -7x | 9.9x |
Thu, 30 Jun 2022 | HK$369.6b | HK$33.0b | -HK$46,590,730,202.00 | 14.8x | -7.9x | 11.2x |
Sat, 28 May 2022 | HK$319.3b | HK$34.0b | -HK$45,701,495,668.00 | 12.7x | -7x | 9.4x |
Mon, 25 Apr 2022 | HK$331.6b | HK$35.8b | -HK$45,369,217,033.00 | 12.9x | -7.3x | 9.3x |
Wed, 23 Mar 2022 | HK$321.5b | HK$34.9b | -HK$35,543,106,551.00 | 13.4x | -9x | 9.2x |
Fri, 18 Feb 2022 | HK$314.9b | HK$31.2b | -HK$31,991,144,778.00 | 12.6x | -9.8x | 10.1x |
Sun, 16 Jan 2022 | HK$379.4b | HK$31.1b | -HK$31,846,983,742.00 | 13.3x | -11.9x | 12.2x |
Tue, 14 Dec 2021 | HK$470.4b | HK$31.1b | -HK$31,827,233,997.00 | 13.7x | -14.8x | 15.1x |
Thu, 11 Nov 2021 | HK$487.2b | HK$31.0b | -HK$31,676,947,042.00 | 14.2x | -15.4x | 15.7x |
Sat, 09 Oct 2021 | HK$495.2b | HK$30.5b | -HK$31,535,187,052.00 | 14.9x | -15.7x | 16.2x |
Mon, 06 Sep 2021 | HK$545.4b | HK$30.4b | -HK$31,412,511,864.39 | 18.2x | -17.4x | 17.9x |
Wed, 04 Aug 2021 | HK$571.3b | HK$30.2b | -HK$32,058,827,347.35 | 13.6x | -17.8x | 18.9x |
Sat, 08 May 2021 | HK$572.9b | HK$27.8b | -HK$26,637,487,691.09 | 16.9x | -21.5x | 20.6x |
-19.3x
How does Hong Kong Biotech compare with similar industries?
HK Market | 1.55% | |
Healthcare | 4.12% | |
Biotech | 8.34% | |
Biotech | 8.34% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$147.10 | 23.3% +HK$6.1b | n/a | PS19.7x | |
1801 Innovent Biologics | HK$42.30 | 5.8% +HK$3.7b | 11.6% | PS12.6x | |
9926 Akeso | HK$51.85 | 8.8% +HK$3.5b | 20.4% | PE20.2x | |
9995 RemeGen | HK$29.75 | 23.7% +HK$3.1b | -40.5% | PS13.6x | |
2162 Keymed Biosciences | HK$39.35 | 16.8% +HK$1.6b | -36.6% | PS30.6x |